THALITONE Drug Patent Profile
When do Thalitone patents expire, and what generic alternatives are available?
Thalitone is a drug marketed by Casper Pharma Llc and Monarch Pharms and is included in two NDAs.
The generic ingredient in THALITONE is chlorthalidone. There is one drug master file entry for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the chlorthalidone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Thalitone
A generic version of THALITONE was approved as chlorthalidone by SUN PHARM INDUSTRIES on July 21st, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for THALITONE?
- What are the global sales for THALITONE?
- What is Average Wholesale Price for THALITONE?
Summary for THALITONE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 93 |
| Clinical Trials: | 4 |
| Patent Applications: | 4,055 |
| Drug Prices: | Drug price information for THALITONE |
| What excipients (inactive ingredients) are in THALITONE? | THALITONE excipients list |
| DailyMed Link: | THALITONE at DailyMed |
Recent Clinical Trials for THALITONE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Anthony J Viera, MD, MPH | N/A |
| North Carolina Translational and Clinical Sciences Institute | N/A |
| Virginia Commonwealth University | Phase 4 |
Pharmacology for THALITONE
| Drug Class | Thiazide-like Diuretic |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for THALITONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Casper Pharma Llc | THALITONE | chlorthalidone | TABLET;ORAL | 019574-001 | Dec 20, 1988 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Casper Pharma Llc | THALITONE | chlorthalidone | TABLET;ORAL | 019574-002 | Feb 12, 1992 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Monarch Pharms | THALITONE | chlorthalidone | TABLET;ORAL | 088051-001 | Nov 12, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for THALITONE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Casper Pharma Llc | THALITONE | chlorthalidone | TABLET;ORAL | 019574-001 | Dec 20, 1988 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for THALITONE
See the table below for patents covering THALITONE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 31024 | ⤷ Start Trial | |
| Australia | 2569684 | ⤷ Start Trial | |
| Australia | 562929 | ⤷ Start Trial | |
| Canada | 1212329 | DISPERSIONS DE CHLORTHALIDONE (CHLORTHALIDONE DISPERSIONS) | ⤷ Start Trial |
| German Democratic Republic | 220225 | VERFAHREN ZUR HERSTELLUNG EINER FESTKOERPERDISPERSION VON CHLORTHALIDON | ⤷ Start Trial |
| Germany | 3467707 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch